About Us
Dedicated to revolutionizing new drug discovery and development
Overview
LigaChem Biosciences, Inc. (LCB) is a clinical stage biopharmaceutical company dedicated to the discovery and development of innovative medicines by leveraging our medicinal chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases of highly unmet medical needs.
LCB is focusing its R&D capabilities on the ADC and Immuno-Oncology drugs using next generation ADC platform that combines our core medicinal chemistry capabilities with biologics.
LCB is focusing its R&D capabilities on the ADC and Immuno-Oncology drugs using next generation ADC platform that combines our core medicinal chemistry capabilities with biologics.
LigaChem Biosciences is dedicated to developing novel therapeutics, leveraging extensive experience and expertise in medicinal chemistry.
Leveraging our advanced technologies, we deliver next-generation ADC and immuno-oncology therapeutics.
Leveraging our advanced technologies, we deliver next-generation ADC and immuno-oncology therapeutics.
Leveraging
Chemistry for
Better
therapeutics
Chemistry for
Better
therapeutics
Leaping into a leading oncology biopharmaceutical beyond ADC
Global Competitiveness
- Proprietary ADC technology overcoming limitations of conventional treatments
- A robust pipeline of ADCs leveraging core technologies
- Outstanding superiority of ADC platform validated in clinical trials
- Achievements in ADC Product/Platform global licensing deals
Linking
Chemistry with
Biologics
Chemistry with
Biologics
New Growth Drivers
- Persistant innovation of ADC platform for sharpening competitive edge
- Recurring revenue through multiple global licensing deals
- Shifting into a global biopharmaceutical through commercialization
- Leaping into a leading oncology biopharmaceutical beyond ADC